Search Within

Andrew D Zelenetz

Formats
  1. Meeting Abstract (461)
  2. Journal Article (288)
  3. Research Letter (14)
  4. Book Section (7)
  5. Guidelines (5)
  6. Conference Paper (3)
  7. Correspondence (3)
  8. Editorial (3)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (785)
  2. Department of Medicine (785)
  3. Hematologic Malignancies, Division of (785)
  4. Lymphoma (785)
  5. Survivorship Research (234)
  6. Population Sciences Research Program (189)

More Groups

People
  1. Craig Moskowitz (207)
  2. Ariela Noy (188)
  3. Paul Hamlin (187)
  4. Steven Horwitz (169)
  5. David Straus (163)
  6. Maria Palomba (143)

More People

Years
  1. 2025 (8)
  2. 2024 (31)
  3. 2023 (43)
  4. 2022 (30)
  5. 2021 (29)
  6. 2020 (32)

More Years

Publications
  1. Blood (329)
  2. Journal of Clinical Oncology (83)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (34)
  5. Leukemia and Lymphoma (31)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (341)
  2. American Society of Clinical Oncology (85)
  3. John Wiley & Sons (41)
  4. Harborside Press (35)
  5. Elsevier Inc. (31)
  6. Oxford University Press (31)

More Publishers

Results (785)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A novel gene STORP (stomatin-related protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22
    Journal Article

    Gilles, F.; Glenn, M.; Goy, A.; Remache, Y.; Zelenetz, A. D.
    European Journal of Haematology (2000)

    Fulltext@MSK | Save
  • Physical linkage of the lysyl oxidase-like (LOXL1) gene to the PML gene on human chromosome 15q22
    Journal Article

    Goy, A.; Gilles, F.; Remache, Y.; Zelenetz, A. D.
    Cytogenetics and Cell Genetics (2000)

    Fulltext@MSK | Save
  • High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis
    Journal Article

    Kewalramani, T.; Zelenetz, A. D.; Hedrick, E. E.; Donnelly, G. B.; Hunte, S.; Priovolos, A. C.; Qin, J.; Lyons, N. C.; Yahalom, J.; Nimer, S. D.; more...
    Blood (2000)

    Fulltext@MSK | Save
  • MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma
    Journal Article

    Gilles, F.; Goy, A.; Remache, Y.; Shue, P.; Zelenetz, A. D.
    Blood (2000)

    Fulltext@MSK | Save
  • NCCN practice guidelines for Hodgkin's disease
    Journal Article

    Hoppe, R. T.; Abrams, R.; Bernstein, S.; Bierman, P.; Bloomfield, C. D.; Cox, J.; Gordon, L.; Horning, S.; Kaminski, M.; Love, G.; more...
    Oncology (Norwalk) (1999)

    Fulltext@MSK | Save
  • Phase II trial of docetaxel and vinorelbine in advanced non-small cell lung cancer (NSCLS) with analysis of bcl-2 and bax expression
    Meeting Abstract

    Krug, L. M.; Filippa, D. A.; Kris, M. G.; Zelenetz, A.; Heelan, R. T.; Grant, S. C.; Ng, K. K.; Pizzo, B. A.; Miller, V. A.
    Proceedings of the American Association for Cancer Research Annual Meeting (1999)

    Fulltext@MSK | Save
  • Rituximab + donor lymphocyte infusions for relapsed B cell malignancies post allogeneic transplant
    Meeting Abstract

    Zelenetz, A. D.; Holman, P.; Horvath, K.; Duun, K.; Kunkel, L. A.
    Blood (1999)

    Fulltext@MSK | Save
  • Cloning of the breakpoint of the (1;14)(q21;q32) translocation from a new lymphoma cell line SKI-1-DLCL
    Meeting Abstract

    Gilles, F.; Goy, A.; Remache, Y.; Shue, P.; Portlock, C.; Craig, R.; Zelenetz, A.
    Experimental Hematology (1999)

    Fulltext@MSK | Save
  • Iodine I 131 tositumomab for patients with transformed low-grade non-Hodgkin's lymphoma (NHL): Overall clinical trial experience
    Meeting Abstract

    Zelenetz, A. D.; Vose, J. M.; Knox, S.; Magnuson, D. E.; Kroll, S.; Tidmarsh, G.; Kaminski, M. S.
    Blood (1999)

    Fulltext@MSK | Save
  • Factors predicting outcome in patients with primary refractory intermediate grade lymphoma (IGL) eligible for high dose chemoradiotherapy (HDT) and autologous stem cell transplant (ASCT)
    Meeting Abstract

    Kewalramani, T.; Hedrick, E. E.; Donnelly, G. B.; Satagopan, J. M.; Hunte, S.; Priovolos, A.; Zelenetz, A. D.; Nimer, S. D.; Moskowitz, C. H.
    Blood (1999)

    Fulltext@MSK | Save